Transgene Hopes To Finally Catch The Wave In Virus Based Immunotherapies
Transgene's CEO discusses its immunotherapy pipeline, coming catalysts, and why the French biotech may soon be swept up by growing interest in oncolytic viruses.
You may also be interested in...
Paying €210m for a company that only has preclinical programs may seem steep but BI is clearly impressed with the progress being made by its Austrian partner's lead candidate.
Emerging Company Profile: Switzerland-based Anjarium Biosciences AG has successfully raised $61m in a series A financing that will fund expansion of its novel proprietary platform and development of a nascent pipeline of non-viral gene therapies.
Incyte welcomed FDA approval of its ruxolitinib cream, a selective JAK1/JAK2 inhibitor, as a treatment for atopic dermatitis, but criticized the boxed warnings label assigned to it.